Roche’s neuromyelitis optica spectrum disorder (NMOSD) treatment ‘Enspryng’ was approved in Korea.

On the 25th, Roche Korea announced that the Ministry of Food and Drug Safety (MFDS) approved Enspryng (satralizumab) for the treatment of adults with aquaporin-4 antibody (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD),

NMOSD is a rare autoimmune disorder of the central nervous system that primarily damages the optic nerve and spinal cord, causing loss of vision and neurological damage.

Although its clinical characteristics are similar to multiple sclerosis, over half of the patients with NMOSD experience severe loss of vision and gait disturb